Ouyang J - Search Results

1

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Among authors: ouyang j. Clin J Am Soc Nephrol. 2016 May 6;11(5):803-811. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23. Clin J Am Soc Nephrol. 2016. PMID: 26912543 Free PMC article. Clinical Trial.

2

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators. Gheorghiade M, et al. Among authors: ouyang j. Circulation. 2003 Jun 3;107(21):2690-6. doi: 10.1161/01.CIR.0000070422.41439.04. Epub 2003 May 12. Circulation. 2003. PMID: 12742979 Clinical Trial.

3

Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.

Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C; Tolvaptan Investigators. Gheorghiade M, et al. Among authors: ouyang j. Am J Cardiol. 2006 Apr 1;97(7):1064-7. doi: 10.1016/j.amjcard.2005.10.050. Epub 2006 Feb 17. Am J Cardiol. 2006. PMID: 16563917 Clinical Trial.

4

Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia.

Josiassen RC, Goldman M, Jessani M, Shaughnessy RA, Albazzaz A, Lee J, Ouyang J, Orlandi C, Czerwiec F. Josiassen RC, et al. Among authors: ouyang j. Biol Psychiatry. 2008 Dec 15;64(12):1097-100. doi: 10.1016/j.biopsych.2008.06.017. Epub 2008 Aug 9. Biol Psychiatry. 2008. PMID: 18692175 Clinical Trial.

5

Oral tolvaptan is safe and effective in chronic hyponatremia.

Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Berl T, et al. Among authors: ouyang j. J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. J Am Soc Nephrol. 2010. PMID: 20185637 Free PMC article. Clinical Trial.

6

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS. Irazabal MV, et al. Among authors: ouyang j. Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4. Kidney Int. 2011. PMID: 21544064 Free article. Clinical Trial.

7

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators. Higashihara E, et al. Among authors: ouyang j. Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8. Clin J Am Soc Nephrol. 2011. PMID: 21903984 Free PMC article. Clinical Trial.

8

Vaptans: a potential new approach for treating chronic hyponatremia in psychotic patients.

Josiassen RC, Curtis JL, Shaughnessy RA, Filmyer DM, Geboy AG, Skuban N, Ouyang J, Czerwiec F. Josiassen RC, et al. Among authors: ouyang j. Clin Schizophr Relat Psychoses. 2012 Apr;6(1):21-6. doi: 10.3371/CSRP.6.1.3. Clin Schizophr Relat Psychoses. 2012. PMID: 22453866 Clinical Trial.

9

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Among authors: ouyang j. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.

10

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Boertien WE, et al. Among authors: ouyang j. Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15. Am J Kidney Dis. 2015. PMID: 25600953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,293 results

Search Page